Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial

E. Bertini, E. Dessaud, E. Mercuri, F. Muntoni, J. Kirschner, C. Reid, A. Lusakowska, G.P. Comi, J.-M. Cuisset, J.-L. Abitbol, B. Scherrer, P.S. Ducray, J. Buchbjerg, E. Vianna, W.L. van der Pol, C. Vuillerot, T. Blaettler, P. Fontoura, C. André, C. BrunoB. Chabrol, N. Deconinck, B. Estournet, S. Fontaine-Carbonnel, N. Goemans, K. Gorni, A. Govoni, M. Guglieri, H. Lochmuller, F. Magri, M. Mayer, W. Müller-Felber, F. Rivier, H. Roper, U. Schara, M. Scoto, L. van den Berg, G. Vita, M.C. Walter

Research output: Contribution to journalArticlepeer-review

Cite this